Related references
Note: Only part of the references are listed.Astragaloside IV enhances taxol chemosensitivity of breast cancer via caveolin-1-targeting oxidant damage
Yifeng Zheng et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Low serum creatinine predicts risk for type 2 diabetes
Xue Bao et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2018)
Astragaloside suppresses apoptosis of the podocytes in rats with diabetic nephropathy via miR-378/TRAF5 signaling pathway
Xiao Lei et al.
LIFE SCIENCES (2018)
Astragaloside IV improves vascular endothelial dysfunction by inhibiting the TLR4/NF-κB signaling pathway
Bin Leng et al.
LIFE SCIENCES (2018)
Diabetic retinopathy, metabolic memory and epigenetic modifications
Renu A. Kowluru
VISION RESEARCH (2017)
Diabetes-Induced Reactive Oxygen Species: Mechanism of Their Generation and Role in Renal Injury
Selim Fakhruddin et al.
JOURNAL OF DIABETES RESEARCH (2017)
Astragaloside IV ameliorates diabetic nephropathy by modulating the mitochondrial quality control network
Xinhui Liu et al.
PLOS ONE (2017)
Astragaloside IV Attenuates Podocyte Apoptosis Mediated by Endoplasmic Reticulum Stress through Upregulating Sarco/Endoplasmic Reticulum Ca2+-ATPase 2 Expression in Diabetic Nephropathy
Hengjiang Guo et al.
FRONTIERS IN PHARMACOLOGY (2016)
SIRT1 protects against myocardial ischemia-reperfusion injury via activating eNOS in diabetic rats
Mingge Ding et al.
CARDIOVASCULAR DIABETOLOGY (2015)
Effects of Astragaloside IV on diabetic nephropathy in rats
W. -S. Lu et al.
GENETICS AND MOLECULAR RESEARCH (2015)
Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress
Zeng Si Wang et al.
BMC NEPHROLOGY (2015)
Down-Regulation of PERK-ATF4-CHOP Pathway by Astragaloside IV is Associated with the Inhibition of Endoplasmic Reticulum Stress-Induced Podocyte Apoptosis in Diabetic Rats
Yifang Chen et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2014)
Astragaloside IV ameliorates diabetic nephropathy involving protection of podocytes in streptozotocin induced diabetic rats
Jianguo Chen et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Astragaloside IV inhibits renal tubulointerstitial fibrosis by blocking TGF-β/Smad signaling pathway in vivo and in vitro
Li Wang et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2014)
Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NF-κB pathway under high glucose conditions
Li Sun et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2014)
Vascular Endothelial Growth Factor-Receptor 1 Inhibition Aggravates Diabetic Nephropathy through eNOS Signaling Pathway in db/db Mice
Keun Suk Yang et al.
PLOS ONE (2014)
Ferulic acid combined with astragaloside IV protects against vascular endothelial dysfunction in diabetic rats
Yonghui Yin et al.
BIOSCIENCE TRENDS (2014)
Role of Endothelial Nitric Oxide Synthase in Diabetic Nephropathy: Lessons from Diabetic eNOS Knockout Mice
Takamune Takahashi et al.
JOURNAL OF DIABETES RESEARCH (2014)
Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-κB-mediated inflammatory genes expression
Dingkun Gui et al.
CYTOKINE (2013)
Aberrant Activation of the Intrarenal Renin-Angiotensin System in the Developing Kidneys of Type 2 Diabetic Rats
Y. -Y. Fan et al.
HORMONE AND METABOLIC RESEARCH (2013)
Astragaloside IV Stimulates Angiogenesis and Increases Nitric Oxide Accumulation via JAK2/STAT3 and ERK1/2 Pathway
Shi-Guang Wang et al.
MOLECULES (2013)
Improvement of endothelial nitric oxide synthase activity retards the progression of diabetic nephropathy in db/db mice
Huifang Cheng et al.
KIDNEY INTERNATIONAL (2012)
Astragaloside IV, a Novel Antioxidant, Prevents Glucose-Induced Podocyte Apoptosis In Vitro and In Vivo
Dingkun Gui et al.
PLOS ONE (2012)
Long-Term Administration of the Histone Deacetylase Inhibitor Vorinostat Attenuates Renal Injury in Experimental Diabetes through an Endothelial Nitric Oxide Synthase-Dependent Mechanism
Andrew Advani et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Molecular Insights and Therapeutic Targets for Diabetic Endothelial Dysfunction
Jian Xu et al.
CIRCULATION (2009)
Glomerular endothelial NOS (eNOS) expression in type 2 diabetic patients with nephropathy
Radko Komers et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2008)
Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy
Bernd Hohenstein et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2008)
Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes
Christian Rask-Madsen et al.
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2007)
Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice
Hui John Zhao et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Altered endothelial nitric oxide synthase targeting and conformation and caveolin-1 expression in the diabetic kidney
Radko Komers et al.
DIABETES (2006)
Characterization of susceptibility of inbred mouse strains to diabetic nephropathy
ZH Qi et al.
DIABETES (2005)
Mouse models of diabetic nephropathy
MD Breyer et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Angiogenesis induced by endothelial nitric oxide synthase gene through vascular endothelial growth factor expression in a rat hindlimb ischemia model
T Namba et al.
CIRCULATION (2003)
Protective role of endothelial nitric oxide synthase
EWJA Albrecht et al.
JOURNAL OF PATHOLOGY (2003)
Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis
L Rössig et al.
CIRCULATION RESEARCH (2002)
Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy
YG Kim et al.
KIDNEY INTERNATIONAL (2000)
Acute modulation of endothelial Akt/PKB activity alters nitric oxide-dependent vasomotor activity in vivo
ZY Luo et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Share Paper
